Tolerability of Postexposure Prophylaxis with the Combination of Zidovudine-Lamivudine and Lopinavir-Ritonavir for HIV Infection
- 15 January 2005
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (2) , 303-305
- https://doi.org/10.1086/426589
Abstract
Tolerability of the combination of zidovudine-lamivudine and lopinavir-ritonavir as postexposure prophylaxis (PEP) for human immunodeficiency virus infection was prospectively assessed. A total of 121 patients were enrolled in the study; 23 patients discontinued PEP prematurely for reasons other than adverse events. Of the other 98 patients, 58 (59%) experienced adverse effects, which led to premature PEP discontinuation in 20 cases (20%).Keywords
This publication has 8 references indexed in Scilit:
- Lopinavir–ritonavir (Kaletra) and lithiasisAIDS, 2004
- Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians’ experiences and attitudesAIDS, 2002
- Tolerability of Postexposure Prophylaxis with Zidovudine, Lamivudine, and Nelfinavir for Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 2001
- Tolerability of Postexposure Antiretroviral Prophylaxis for Occupational Exposures to HIVDrug Safety, 2001
- Experience of Healthcare Workers Taking Postexposure Prophylaxis After Occupational HIV Exposures: Findings of the HIV Postexposure Prophylaxis RegistryInfection Control & Hospital Epidemiology, 2000
- Tolerability and side-effects of post-exposure prophylaxis for HIV infectionThe Lancet, 2000
- Transmission of antiretroviral-drug-resistant HIV-1 variantsThe Lancet, 1999
- Zidovudine toxicity in uninfected healthcare workersThe American Journal of Medicine, 1997